Evidence map›Paper›PMID 31157010›Full record

ArticleEuropean journal of hospital pharmacy : science and practice2018

Compatibility of proton pump inhibitors in a preservative-free suspending vehicle.

Hudson C Polonini, Sharlene L Silva, Shirley Loures, Rachel Almy, Antoine Balland, Marcos Antônio F Brandão, Anderson O Ferreira

Open access · bronzeAbstract read
In one paragraph

Article in European journal of hospital pharmacy : science and practice, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.3field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. A Critical Assessment of Extemporaneous Formulations for Proton Pump Inhibitors: The Importance of Proper Vehicle Selection.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2022
    Article
  6. Article
  7. Paving the way for small-molecule drug discovery.American journal of translational research · 2021
    Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Hudson C PoloniniOrtofarma-Quality Control Laboratories, Matias Barbosa, MG, Brazil.
Sharlene L SilvaOrtofarma-Quality Control Laboratories, Matias Barbosa, MG, Brazil.
Shirley LouresOrtofarma-Quality Control Laboratories, Matias Barbosa, MG, Brazil.
Rachel AlmyEurofins-Pharma Quality Control, Sainte Croix en Plaine, France.
Antoine BallandEurofins-Pharma Quality Control, Sainte Croix en Plaine, France.
Marcos Antônio F BrandãoOrtofarma-Quality Control Laboratories, Matias Barbosa, MG, Brazil.
Anderson O FerreiraOrtofarma-Quality Control Laboratories, Matias Barbosa, MG, Brazil.
Eurofins (France) · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo evaluate the microbiological and physicochemical compatibility of commonly used proton pump inhibitors (PPIs) esomeprazole, lansoprazole, omeprazole and pantoprazole compounded at a single concentration using SyrSpend SF Alka and stored at refrigerated temperatures (omeprazole was also stored at room temperature because it has the most widespread use).

methodsCompatibility was assessed by measuring the per cent recovery at varying time points throughout a 90-day period. Quantification of the APIs was performed by a validated high performance liquid chromatography (HPLC-UV) method. This same assay was also used to determine the dosage content uniformity of the suspensions. Microbiological stability ('test in use') was assessed during 60 days and total aerobic microbial count (TAMC), total combined yeasts and moulds count (TYMC), detection of

resultsBeyond-use dates of maximum 60 days for omeprazole (5 mg/mL), pantoprazole (3 mg/mL) and esomeprazole (3 mg/mL) were established. All suspensions that met the physicochemical criteria for stability also met the content uniformity criteria. The suspensions showed no antimicrobial efficiency against bacteria, yeasts and moulds as SyrSpend SF Alka is an unpreserved vehicle, but the 'test in use' showed that the suspensions can remain microbiologically stable for up to 60 days.

conclusionsSyrSpend SF Alka can be used to compound palatable (taste-masking properties) preservative-free oral suspensions with almost all commonly used PPIs.

Indexed as

DRUG MANUFACTURING / PREPARATION / COMPOUNDINGOral suspensionProton pump inhibitorsSTABILITY AND INCOMPATIBILITY

Identifiers

PMID31157010
PMCPMC6452384
OpenAlexW2554044674

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.